MA29400B1 - Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence - Google Patents

Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence

Info

Publication number
MA29400B1
MA29400B1 MA30310A MA30310A MA29400B1 MA 29400 B1 MA29400 B1 MA 29400B1 MA 30310 A MA30310 A MA 30310A MA 30310 A MA30310 A MA 30310A MA 29400 B1 MA29400 B1 MA 29400B1
Authority
MA
Morocco
Prior art keywords
dementia
disorder
prevention
agent
treatment
Prior art date
Application number
MA30310A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29400B1 publication Critical patent/MA29400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN AGENT POUR LA PRÉVENTION OU LE TRAITEMENT D'UN TROUBLE NOCTURNE DU COMPORTEMENT ASSOCIÉ À LA DÉMENCE, COMPRENANT DU (S)-N-[2-(1,6,7,8-TÉTRAHYDRO-2H-INDÉNO[5,4-B]FURANE-8- YL)ÉTHYLE]PROPIONAMIDE.
MA30310A 2005-04-04 2007-10-25 Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence MA29400B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107673 2005-04-04

Publications (1)

Publication Number Publication Date
MA29400B1 true MA29400B1 (fr) 2008-04-01

Family

ID=37073568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30310A MA29400B1 (fr) 2005-04-04 2007-10-25 Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence

Country Status (20)

Country Link
US (1) US20090306200A1 (fr)
EP (1) EP1867642A4 (fr)
JP (1) JP5244384B2 (fr)
KR (1) KR20070118101A (fr)
CN (1) CN101146787A (fr)
AR (1) AR054246A1 (fr)
AU (1) AU2006231759A1 (fr)
BR (1) BRPI0609964A2 (fr)
CA (1) CA2601988A1 (fr)
CL (1) CL2009001914A1 (fr)
CR (1) CR9376A (fr)
IL (1) IL185936A0 (fr)
MA (1) MA29400B1 (fr)
MY (1) MY148806A (fr)
NO (1) NO20075600L (fr)
PE (1) PE20061292A1 (fr)
RU (1) RU2007140876A (fr)
TW (1) TW200637541A (fr)
WO (1) WO2006107027A1 (fr)
ZA (1) ZA200708444B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
AU2017205519B2 (en) 2016-01-08 2022-01-27 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for delirium

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3034239A (en) * 1961-04-05 1962-05-15 Arthur P Waterson Land leveler
US6638963B1 (en) * 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
WO2004015081A2 (fr) * 2002-08-08 2004-02-19 Irm Llc Procedes de traitement de troubles de phases du rythme circadien

Also Published As

Publication number Publication date
CR9376A (es) 2007-12-07
ZA200708444B (en) 2009-03-25
EP1867642A1 (fr) 2007-12-19
MY148806A (en) 2013-05-31
WO2006107027A1 (fr) 2006-10-12
KR20070118101A (ko) 2007-12-13
RU2007140876A (ru) 2009-05-20
EP1867642A4 (fr) 2009-04-01
CN101146787A (zh) 2008-03-19
US20090306200A1 (en) 2009-12-10
AR054246A1 (es) 2007-06-13
JPWO2006107027A1 (ja) 2008-09-25
CA2601988A1 (fr) 2006-10-12
AU2006231759A1 (en) 2006-10-12
JP5244384B2 (ja) 2013-07-24
PE20061292A1 (es) 2006-12-23
TW200637541A (en) 2006-11-01
CL2009001914A1 (es) 2010-02-12
IL185936A0 (en) 2008-01-06
NO20075600L (no) 2007-12-21
BRPI0609964A2 (pt) 2011-10-11

Similar Documents

Publication Publication Date Title
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
EP1875894A3 (fr) Utilisation d'au moins un dérivé C-glycoside à titre d'agent apaisant
ATE368031T1 (de) Neue gamma secretase inhibitoren
TW200722100A (en) A therapeutic agent for a β related disorders
JP2009519986A5 (fr)
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MX2008001549A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de esquizofrenia y otras psicosis.
NO20075599L (no) Profylaktisk eller terapeutisk middel mot depresjon eller angstforstyrrelser
ZA200801171B (en) 3, IIB-CIS-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
WO2009015369A3 (fr) Composés qui inhibent l'activité de la bêta-sécrétase et procédés d'utilisation de ceux-ci
ITRM20050446A1 (it) Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
EP1773970A4 (fr) Formules de lubrifiants pour le traitement de toles
WO2005042021A3 (fr) Composition pharmaceutique contenant un agoniste des recepteurs beta-3-adrenergiques et un antagoniste alpha et/ou un inhibiteur de la 5-alpha-reductase
MA29400B1 (fr) Agent pour la prevention ou le traitement d'un trouble nocturne du comportement associe a la demence
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
MX2010001304A (es) Compuestos terapeuticos.
FR2890304B1 (fr) Un dispositif pour mesurer la resistance a la deformation d'une cornee.
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
MA31993B1 (fr) Nouvel usage medical des sels de 3-(2,2,2-trimethylhydrazinium) propionate
ATE257822T1 (de) Aminoiminochinon und aminochinon alkaloid verbindungen als caspase inhibitoren
MXPA05009243A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados.
EP1681063A4 (fr) Agent permettant d'attenuer des troubles mentaux
FR2867979A1 (fr) Nouvelle application therapeutique d'un derive de la phenothiazine
EP1842556A4 (fr) Agent therapeutique pour le traitement du trouble de l'hyperactivite avec deficit d'attention
BR0316369B1 (pt) vestimenta para proteção parcial do corpo contra agentes biológicos.